CONCLUSION
diabetes, ASCVD, T2DM, dyslipidemia
DIABETES, ASCVD, DYSLIPIDEMIA
To our knowledge, this is the first randomized controlled study to evaluate the effect of 6-week treatment with xuezhikang 1.2 g/day and pravastatin 20 mg/day on fasting and postprandial TG levels as well as other blood lipid parameters in patients with T2DM and dyslipidemia without ASCVD. The results will provide more information on how to optimize lipid control for patients with diabetes in the primary prevention of ASCVD.